Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Apr 24  •  04:00PM ET
1.67
Dollar change
-0.04
Percentage change
-2.34
%
Index
-
P/E
-
EPS (ttm)
-31.01
Insider Own
8.57%
Shs Outstand
3.60M
Perf Week
7.05%
Market Cap
6.02M
Forward P/E
-
EPS next Y
-
Insider Trans
0.00%
Shs Float
3.29M
Perf Month
-15.23%
Enterprise Value
-4.62M
PEG
-
EPS next Q
-
Inst Own
5.16%
Perf Quarter
-44.15%
Income
-46.90M
P/S
14.33
EPS this Y
-
Inst Trans
-5.12%
Perf Half Y
-82.54%
Sales
0.42M
P/B
0.17
EPS next Y
-
ROA
-95.40%
Perf YTD
-66.98%
Book/sh
9.85
P/C
0.51
EPS next 5Y
-
ROE
-125.15%
52W High
46.50 -96.41%
Perf Year
-84.54%
Cash/sh
3.30
P/FCF
-
EPS past 3/5Y
-37.47% -
ROIC
-221.18%
52W Low
1.35 23.70%
Perf 3Y
-96.02%
Dividend Est.
-
EV/EBITDA
-
Sales past 3/5Y
-76.97% -64.54%
Gross Margin
-217.83%
Volatility
8.99% 9.23%
Perf 5Y
-99.38%
Dividend TTM
-
EV/Sales
-11.00
EPS Y/Y TTM
15.01%
Oper. Margin
-7529.23%
ATR (14)
0.21
Perf 10Y
-
Dividend Ex-Date
-
Quick Ratio
3.59
Sales Y/Y TTM
-45.69%
Profit Margin
-11213.62%
RSI (14)
45.71
Dividend Gr. 3/5Y
- -
Current Ratio
3.87
EPS Q/Q
-22.74%
SMA20
6.79%
Beta
1.36
Payout
-
Debt/Eq
0.06
Sales Q/Q
-60.06%
SMA50
-20.41%
Rel Volume
0.06
Prev Close
1.71
Employees
115
LT Debt/Eq
0.03
SMA200
-76.87%
Avg Volume
1.18M
Price
1.67
IPO
Jul 12, 2017
Option/Short
No / Yes
Trades
Volume
74,384
Change
-2.34%
Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.